Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Recombinant Norovirus Hexavalent Vaccine in Healthy Adults
NCT05805618Phase 1Unknown
- Sponsor
- Syneos Health
- Start
- Jul 2024
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial in norovirus infection comparing KH002 with Matching Placebo (2 arms). Primary endpoints: Incidence of solicited adverse events at 7 days, Incidence of unsolicited adverse events at 28 days and 2 more. Status: unknown.
02
Drugs
KH002
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT05805618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805618.